A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status: Open to Accrual
Read More

Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of Olaparib Followed by Adjuvant Combination of Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases

Status: Open to Accrual Read More

A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

Status: Open to Accrual
Read More

Phase II Study of The Combination of Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Status: Open to Accrual
Read More

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Status: Open to Accrual
Read More